Cargando…

Folic acid receptor-targeted human serum albumin nanoparticle formulation of cabazitaxel for tumor therapy

BACKGROUND: We previously developed cabazitaxel (CTX)-loaded human serum albumin nanoparticles (NPs-CTX) via a self-assembly method, and these NPs showed efficacy in prostate cancer therapy. Many studies have shown that the levels of folic acid (FA) receptor on the surface of various tumor cells are...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Yating, Zhao, Yarong, Teng, Shanshan, Hao, Fei, Zhang, Huan, Meng, Fanchao, Zhao, Xiuting, Zheng, Xiaolong, Bi, Ye, Yao, Yicheng, Lee, Robert J, Teng, Lesheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6306057/
https://www.ncbi.nlm.nih.gov/pubmed/30613142
http://dx.doi.org/10.2147/IJN.S181296
_version_ 1783382703252439040
author Sun, Yating
Zhao, Yarong
Teng, Shanshan
Hao, Fei
Zhang, Huan
Meng, Fanchao
Zhao, Xiuting
Zheng, Xiaolong
Bi, Ye
Yao, Yicheng
Lee, Robert J
Teng, Lesheng
author_facet Sun, Yating
Zhao, Yarong
Teng, Shanshan
Hao, Fei
Zhang, Huan
Meng, Fanchao
Zhao, Xiuting
Zheng, Xiaolong
Bi, Ye
Yao, Yicheng
Lee, Robert J
Teng, Lesheng
author_sort Sun, Yating
collection PubMed
description BACKGROUND: We previously developed cabazitaxel (CTX)-loaded human serum albumin nanoparticles (NPs-CTX) via a self-assembly method, and these NPs showed efficacy in prostate cancer therapy. Many studies have shown that the levels of folic acid (FA) receptor on the surface of various tumor cells are high. Therefore, FA-modified NPs-CTX may have enhanced antitumor effects compared with unmodified NPs-CTX. METHODS: NPs-CTX were first prepared via self-assembly, and FA was conjugated on the surface of NPs-CTX through the -NH(2) groups of the NPs to produce FA-NPs-CTX. The FA-NPs-CTX were evaluated in tumor cells with high FA receptor (FR) expression in vitro and in vivo. RESULTS: Both NPs-CTX and FA-NPs-CTX exhibited good stability and morphology. Drug release from the NPs was not affected by FA conjugation. Compared with CTX dissolved in a mixture of Tween 80 and 13% ethanol (w/w) at a ratio of 1:4 (v/v) (Tween-CTX), the two nanoformulations had lower lytic activity against normal red blood cells. However, FA-NPs-CTX showed greater inhibition of tumor cells with overexpressed FR, compared with NPs-CTX, in the cytotoxicity experiments. Moreover, the cellular uptake of FA-NPs-CTX was enhanced through FR-mediated endocytosis in HeLa cells in vitro and HeLa xenograft tumors in vivo. Although Tween-CTX exhibited tumor growth inhibition similar to FA-NPs-CTX in vivo, this inhibition also caused adverse side effects; the median lethal dose (LD50) of Tween-CTX to mice was 5.68 mg/kg, while FA-NPs-CTX-treated mice survived at doses exceeding 400 mg/kg. CONCLUSION: The results showed that FA-NPs-CTX caused inhibition of tumor growth in a manner similar to that of Tween-CTX; however, the safety and tolerability of CTX were greatly improved by FA conjugation compared with those of Tween-CTX. In summary, FA-NPs-CTX have great potential in CTX delivery, and this formulation is a promising candidate for the treatment of cancers with high FR levels.
format Online
Article
Text
id pubmed-6306057
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-63060572019-01-04 Folic acid receptor-targeted human serum albumin nanoparticle formulation of cabazitaxel for tumor therapy Sun, Yating Zhao, Yarong Teng, Shanshan Hao, Fei Zhang, Huan Meng, Fanchao Zhao, Xiuting Zheng, Xiaolong Bi, Ye Yao, Yicheng Lee, Robert J Teng, Lesheng Int J Nanomedicine Original Research BACKGROUND: We previously developed cabazitaxel (CTX)-loaded human serum albumin nanoparticles (NPs-CTX) via a self-assembly method, and these NPs showed efficacy in prostate cancer therapy. Many studies have shown that the levels of folic acid (FA) receptor on the surface of various tumor cells are high. Therefore, FA-modified NPs-CTX may have enhanced antitumor effects compared with unmodified NPs-CTX. METHODS: NPs-CTX were first prepared via self-assembly, and FA was conjugated on the surface of NPs-CTX through the -NH(2) groups of the NPs to produce FA-NPs-CTX. The FA-NPs-CTX were evaluated in tumor cells with high FA receptor (FR) expression in vitro and in vivo. RESULTS: Both NPs-CTX and FA-NPs-CTX exhibited good stability and morphology. Drug release from the NPs was not affected by FA conjugation. Compared with CTX dissolved in a mixture of Tween 80 and 13% ethanol (w/w) at a ratio of 1:4 (v/v) (Tween-CTX), the two nanoformulations had lower lytic activity against normal red blood cells. However, FA-NPs-CTX showed greater inhibition of tumor cells with overexpressed FR, compared with NPs-CTX, in the cytotoxicity experiments. Moreover, the cellular uptake of FA-NPs-CTX was enhanced through FR-mediated endocytosis in HeLa cells in vitro and HeLa xenograft tumors in vivo. Although Tween-CTX exhibited tumor growth inhibition similar to FA-NPs-CTX in vivo, this inhibition also caused adverse side effects; the median lethal dose (LD50) of Tween-CTX to mice was 5.68 mg/kg, while FA-NPs-CTX-treated mice survived at doses exceeding 400 mg/kg. CONCLUSION: The results showed that FA-NPs-CTX caused inhibition of tumor growth in a manner similar to that of Tween-CTX; however, the safety and tolerability of CTX were greatly improved by FA conjugation compared with those of Tween-CTX. In summary, FA-NPs-CTX have great potential in CTX delivery, and this formulation is a promising candidate for the treatment of cancers with high FR levels. Dove Medical Press 2018-12-21 /pmc/articles/PMC6306057/ /pubmed/30613142 http://dx.doi.org/10.2147/IJN.S181296 Text en © 2019 Sun et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Sun, Yating
Zhao, Yarong
Teng, Shanshan
Hao, Fei
Zhang, Huan
Meng, Fanchao
Zhao, Xiuting
Zheng, Xiaolong
Bi, Ye
Yao, Yicheng
Lee, Robert J
Teng, Lesheng
Folic acid receptor-targeted human serum albumin nanoparticle formulation of cabazitaxel for tumor therapy
title Folic acid receptor-targeted human serum albumin nanoparticle formulation of cabazitaxel for tumor therapy
title_full Folic acid receptor-targeted human serum albumin nanoparticle formulation of cabazitaxel for tumor therapy
title_fullStr Folic acid receptor-targeted human serum albumin nanoparticle formulation of cabazitaxel for tumor therapy
title_full_unstemmed Folic acid receptor-targeted human serum albumin nanoparticle formulation of cabazitaxel for tumor therapy
title_short Folic acid receptor-targeted human serum albumin nanoparticle formulation of cabazitaxel for tumor therapy
title_sort folic acid receptor-targeted human serum albumin nanoparticle formulation of cabazitaxel for tumor therapy
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6306057/
https://www.ncbi.nlm.nih.gov/pubmed/30613142
http://dx.doi.org/10.2147/IJN.S181296
work_keys_str_mv AT sunyating folicacidreceptortargetedhumanserumalbuminnanoparticleformulationofcabazitaxelfortumortherapy
AT zhaoyarong folicacidreceptortargetedhumanserumalbuminnanoparticleformulationofcabazitaxelfortumortherapy
AT tengshanshan folicacidreceptortargetedhumanserumalbuminnanoparticleformulationofcabazitaxelfortumortherapy
AT haofei folicacidreceptortargetedhumanserumalbuminnanoparticleformulationofcabazitaxelfortumortherapy
AT zhanghuan folicacidreceptortargetedhumanserumalbuminnanoparticleformulationofcabazitaxelfortumortherapy
AT mengfanchao folicacidreceptortargetedhumanserumalbuminnanoparticleformulationofcabazitaxelfortumortherapy
AT zhaoxiuting folicacidreceptortargetedhumanserumalbuminnanoparticleformulationofcabazitaxelfortumortherapy
AT zhengxiaolong folicacidreceptortargetedhumanserumalbuminnanoparticleformulationofcabazitaxelfortumortherapy
AT biye folicacidreceptortargetedhumanserumalbuminnanoparticleformulationofcabazitaxelfortumortherapy
AT yaoyicheng folicacidreceptortargetedhumanserumalbuminnanoparticleformulationofcabazitaxelfortumortherapy
AT leerobertj folicacidreceptortargetedhumanserumalbuminnanoparticleformulationofcabazitaxelfortumortherapy
AT tenglesheng folicacidreceptortargetedhumanserumalbuminnanoparticleformulationofcabazitaxelfortumortherapy